Published in Am J Gastroenterol on January 10, 2017
Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy? | NCT03347513
Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. Antimicrob Agents Chemother (2017) 0.75
Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol (2017) 0.75
Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. Curr Treat Options Gastroenterol (2017) 0.75
Appropriateness of the study of iron deficiency anemia prior to referral for small bowel evaluation at a tertiary center. World J Gastroenterol (2017) 0.75
A Novel stool PCR Test for Helicobacter pylori may Predict Clarithromycin Resistance and Patient Eradication at a High Rate. J Clin Microbiol (2017) 0.75
Population Knowledge, Attitude, and Practice Regarding Helicobacter pylori Transmission and Outcomes: A Literature Review. Front Public Health (2017) 0.75
Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. Dig Dis Sci (2017) 0.75
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (2008) 33.10
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol (2007) 7.49
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50
Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet (2002) 5.58
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med (2003) 4.65
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet (2012) 4.62
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet (1997) 3.67
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther (2007) 3.53
U.S. outpatient antibiotic prescribing, 2010. N Engl J Med (2013) 3.49
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol (2009) 3.18
Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology (1992) 3.02
Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther (2012) 2.94
Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol (2009) 2.73
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet (2002) 2.71
Review article: Associations between Helicobacter pylori and obesity--an ecological study. Aliment Pharmacol Ther (2014) 2.69
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol (2013) 2.62
Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol (2013) 2.58
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet (2002) 2.52
Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis (2000) 2.52
Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut (2012) 2.49
Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology (2013) 2.49
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol (2011) 2.35
Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol (2013) 2.27
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther (2012) 2.23
Helicobacter pylori infection in Canadian and related Arctic Aboriginal populations. Can J Gastroenterol (2008) 2.22
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood (2008) 2.13
Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol (2002) 2.09
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology (2005) 2.07
Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut (2006) 1.92
Reduced risk of atopic disorders in adults with Helicobacter pylori infection. Eur J Gastroenterol Hepatol (2003) 1.87
Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion (2011) 1.83
Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ (2013) 1.74
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol (2005) 1.72
Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci (2000) 1.71
Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis (2004) 1.63
Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med (2006) 1.62
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther (2003) 1.59
Non-gastrointestinal tract associations of Helicobacter pylori infection. Arch Intern Med (1999) 1.58
Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol (2005) 1.56
Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther (2004) 1.53
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med (2003) 1.51
High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol (2000) 1.49
Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann Hematol (2005) 1.48
A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther (2000) 1.48
Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog (2008) 1.48
Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev (2006) 1.47
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol (2003) 1.46
A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med (1999) 1.44
Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol (2013) 1.41
Does H. pylori eradication therapy benefit patients with hepatic encephalopathy?: systematic review. J Clin Gastroenterol (2014) 1.39
Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings. Am J Gastroenterol (2009) 1.37
Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther (2002) 1.35
Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol (2010) 1.34
Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther (2005) 1.34
Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther (2002) 1.33
Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther (2005) 1.32
Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med (1998) 1.30
Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology (2011) 1.29
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol (2009) 1.29
Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter (1998) 1.27
Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev (2011) 1.26
Initial management strategies for dyspepsia. Cochrane Database Syst Rev (2005) 1.26
Epidemiology of Helicobacter pylori infection. Helicobacter (2014) 1.26
Gastroduodenal Disorders. Gastroenterology (2016) 1.25
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol (2010) 1.24
Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ (2015) 1.24
Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther (2015) 1.22
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother (2009) 1.21
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther (2011) 1.21
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother (2012) 1.20
Epidemiology of Helicobacter pylori infection. Helicobacter (2008) 1.19
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol (2000) 1.18
Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion (2013) 1.17
Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess (2007) 1.17
The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol (2014) 1.17
Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis (2007) 1.15
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J Gastroenterol Hepatol (2008) 1.14
Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter (2010) 1.14
Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter (2014) 1.14
Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol (2001) 1.13
Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci (2014) 1.12
Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter (2000) 1.12
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther (2002) 1.10
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol (2007) 1.10
Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys. Dig Dis Sci (2006) 1.09
Helicobacter pylori infection in Ontario: prevalence and risk factors. Can J Gastroenterol (2007) 1.08
The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community and the potential for parent-to-child transmission. Helicobacter (2004) 1.07
A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol (2015) 2.35
A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol (2016) 0.82
American Gastroenterological Association Institute Technical Review on the Role of Upper Gastrointestinal Biopsy to Evaluate Dyspepsia in the Adult Patient in the Absence of Visible Mucosal Lesions. Gastroenterology (2015) 0.78
How Do US Gastroenterologists Use Over-the-Counter and Prescription Medications in Patients With Gastroesophageal Reflux and Chronic Constipation? Am J Gastroenterol (2015) 0.76
Response to Sorrentino et al. Am J Gastroenterol (2015) 0.75
Response to Georgopoulos et al. Am J Gastroenterol (2017) 0.75
Introduction. J Gastroenterol Hepatol (2017) 0.75
ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol (2017) 0.75
The Light Shines on: American Journal of Gastroenterology 2015. Am J Gastroenterol (2015) 0.75